Marriott Harrison represented a number of leading investors in Caristo’s $16.3m Series A. The firm acted for Oxford Science Enterprises, BGF, Longwall and Oxford Investment Consultants. The funding round was led by Oxford Science Enterprises.
Founded in 2018 by cardiologists at the University of Oxford, Caristo Diagnostics improves health outcomes by leveraging AI algorithms. With their technology, CaRi-Heart, health care professionals can measure coronary inflammation in CT scans, a leading factor in heart attacks. The company will use the funds raised to propel its CaRi-Heart technology into standards of cardiac care on an international standing.
Oxford Science Enterprises is an independent, billion-pound investment company created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford.
BGF, which was set up in 2011 by high-street banks – Barclays, HSBC, Lloyds, Natwest and Standard Chartered – has invested over £3bn in more than 500 companies over 12 years.
Longwall Ventures invests in early-stage businesses that harness the UK’s expertise in science to address global challenges.
Oxford Investment Consultants back extraordinary founders turning scientific research into products addressing the world’s current greatest challenges.